These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 12712329

  • 1. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer.
    Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW.
    J Cancer Res Clin Oncol; 2003 Mar; 129(3):147-53. PubMed ID: 12712329
    [Abstract] [Full Text] [Related]

  • 2. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 3. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P.
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [Abstract] [Full Text] [Related]

  • 4. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014 May; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 5. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, Carreras JL.
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 7. The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma.
    Yang ZY, Hu SL, Shi W, Zhu BL, Xu JY, Zhang YJ.
    Nucl Med Commun; 2011 Nov; 32(11):1018-25. PubMed ID: 21956489
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
    Jung NY, Yoo IR, Kang BJ, Kim SH, Chae BJ, Seo YY.
    Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
    [Abstract] [Full Text] [Related]

  • 9. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, Maes A, Mortelmans L.
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, Cortese AA, Hayes CE, Moe RE.
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [Abstract] [Full Text] [Related]

  • 12. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography.
    Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, Alberini JL, Floiras JL, Goupil A, Pichon MF.
    Clin Breast Cancer; 2001 Oct; 2(3):229-34. PubMed ID: 11899417
    [Abstract] [Full Text] [Related]

  • 13. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.
    Acta Gastroenterol Belg; 2007 Oct; 70(4):331-8. PubMed ID: 18330088
    [Abstract] [Full Text] [Related]

  • 14. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
    Koolen BB, van der Leij F, Vogel WV, Rutgers EJ, Vrancken Peeters MJ, Elkhuizen PH, Valdés Olmos RA.
    Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
    van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, Meijer S, van der Wall E, Buter J, Pinedo HM, Teule GJ, Lammertsma AA.
    J Clin Oncol; 2004 Apr 01; 22(7):1253-9. PubMed ID: 15051773
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
    Landheer ML, Steffens MG, Klinkenbijl JH, Westenberg AH, Oyen WJ.
    Br J Surg; 2005 Nov 01; 92(11):1363-7. PubMed ID: 16187254
    [Abstract] [Full Text] [Related]

  • 20. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Takekuma M, Maeda M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2002 Jun 01; 29(6):797-803. PubMed ID: 12029554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.